Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510230578> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2510230578 abstract "Some antagonists of human growth hor- mone-releasing hormone (hGH-RH) synthesized previously were shown to inhibit in vivo proliferation of various human cancers in nude mice. However, the activity of these analogs requires an increase to assure clinical efficacy. In an attempt to prepare hGH-RH antagonists with a high and protracted activity, we synthesized and biologically tested 22 antagonistic analogs of hGH-RH(1-29)NH2. The ability of the antagonists to inhibit hGH-RH-induced GH release was evaluated in vitro in a superfused rat pituitary system, as well as in vivo after i.v. injection into rats. The binding affinity of the peptides to GH-RH receptors also was determined. All antagonistic an- alogs had the common core sequence (PhAc-Tyrl,D-Arg2, Phe(4-Cl)6 (para-chlorophenylalanine), Abu15 (a-aminobu- tyric acid),Nle27)hGH-RH(1-29)NH2 and contained Arg, D- Arg, homoarginine (Har), norleucine (Nle), and other substi- tutions. The following analogs were determined to have a high and/or protracted antagonistic activity: (PhAc-Tyrl,D- Arg2,Phe (4-Cl) 6,Arg9,Abul5,Nle27,D-Arg29) hGH-RH (1- 29)NH2 (JV-1-10), (PhAc-Tyrl,D-Arg2,Phe(4-Cl)6,Abul5,Nle27, D-Arg28,Har29)hGH-RH(1-29)NH2 (MZ-6-55), (PhAc-Tyrl,D- Arg2,Phe(4-Cl)6,Arg9,Abul5,Nle27,D-Arg28,Har29)hGH-RH(1- 29)NH2 (JV-1-36), and (PhAc-Tyrl,D-Arg2,Phe(4-Cl)6, Har9,Tyr(Me) 10,Abul5,Nle27,D-Arg28,Har29) hGH-RH (1- 29)NH2 (JV-1-38). Among the peptides tested, analog JV-1-36 showed the highest GH-RH antagonistic activity in vitro and also induced a strong and prolonged inhibition of GH release in vivo for at least 30 min. The antagonist JV-1-38 was slightly less potent than JV-1-36 both in vitro and in vivo but proved to be very long-acting in vivo, suppressing the GH-RH-induced GH release even after 60 min. High and protracted in vivo activities of these antagonists indicate an improvement over earlier GH-RH analogs. Some of these hGH-RH antagonists could find clinical applications in the treatment of cancers dependent on insulin-like growth factors I and II." @default.
- W2510230578 created "2016-09-16" @default.
- W2510230578 creator A5008707617 @default.
- W2510230578 creator A5064362567 @default.
- W2510230578 creator A5066730327 @default.
- W2510230578 creator A5067625265 @default.
- W2510230578 creator A5068739269 @default.
- W2510230578 date "2016-01-01" @default.
- W2510230578 modified "2023-09-27" @default.
- W2510230578 title "(inhibitors of GH release/structure-activity relationships/cancer" @default.
- W2510230578 cites W2115304761 @default.
- W2510230578 cites W340450340 @default.
- W2510230578 hasPublicationYear "2016" @default.
- W2510230578 type Work @default.
- W2510230578 sameAs 2510230578 @default.
- W2510230578 citedByCount "0" @default.
- W2510230578 crossrefType "journal-article" @default.
- W2510230578 hasAuthorship W2510230578A5008707617 @default.
- W2510230578 hasAuthorship W2510230578A5064362567 @default.
- W2510230578 hasAuthorship W2510230578A5066730327 @default.
- W2510230578 hasAuthorship W2510230578A5067625265 @default.
- W2510230578 hasAuthorship W2510230578A5068739269 @default.
- W2510230578 hasConcept C126322002 @default.
- W2510230578 hasConcept C134018914 @default.
- W2510230578 hasConcept C150903083 @default.
- W2510230578 hasConcept C170493617 @default.
- W2510230578 hasConcept C185592680 @default.
- W2510230578 hasConcept C202751555 @default.
- W2510230578 hasConcept C207001950 @default.
- W2510230578 hasConcept C2780327651 @default.
- W2510230578 hasConcept C2780912031 @default.
- W2510230578 hasConcept C515207424 @default.
- W2510230578 hasConcept C55493867 @default.
- W2510230578 hasConcept C71240020 @default.
- W2510230578 hasConcept C71924100 @default.
- W2510230578 hasConcept C86803240 @default.
- W2510230578 hasConceptScore W2510230578C126322002 @default.
- W2510230578 hasConceptScore W2510230578C134018914 @default.
- W2510230578 hasConceptScore W2510230578C150903083 @default.
- W2510230578 hasConceptScore W2510230578C170493617 @default.
- W2510230578 hasConceptScore W2510230578C185592680 @default.
- W2510230578 hasConceptScore W2510230578C202751555 @default.
- W2510230578 hasConceptScore W2510230578C207001950 @default.
- W2510230578 hasConceptScore W2510230578C2780327651 @default.
- W2510230578 hasConceptScore W2510230578C2780912031 @default.
- W2510230578 hasConceptScore W2510230578C515207424 @default.
- W2510230578 hasConceptScore W2510230578C55493867 @default.
- W2510230578 hasConceptScore W2510230578C71240020 @default.
- W2510230578 hasConceptScore W2510230578C71924100 @default.
- W2510230578 hasConceptScore W2510230578C86803240 @default.
- W2510230578 hasLocation W25102305781 @default.
- W2510230578 hasOpenAccess W2510230578 @default.
- W2510230578 hasPrimaryLocation W25102305781 @default.
- W2510230578 hasRelatedWork W1966318586 @default.
- W2510230578 hasRelatedWork W1969318893 @default.
- W2510230578 hasRelatedWork W1988091811 @default.
- W2510230578 hasRelatedWork W2003736884 @default.
- W2510230578 hasRelatedWork W2014087852 @default.
- W2510230578 hasRelatedWork W2039077091 @default.
- W2510230578 hasRelatedWork W2055136022 @default.
- W2510230578 hasRelatedWork W2087738562 @default.
- W2510230578 hasRelatedWork W2090657739 @default.
- W2510230578 hasRelatedWork W2091615507 @default.
- W2510230578 hasRelatedWork W2141117807 @default.
- W2510230578 hasRelatedWork W2148064474 @default.
- W2510230578 hasRelatedWork W2249932734 @default.
- W2510230578 hasRelatedWork W2481038694 @default.
- W2510230578 hasRelatedWork W2567582001 @default.
- W2510230578 hasRelatedWork W1542703841 @default.
- W2510230578 hasRelatedWork W1998929789 @default.
- W2510230578 hasRelatedWork W2769111741 @default.
- W2510230578 hasRelatedWork W2771094268 @default.
- W2510230578 hasRelatedWork W2875128230 @default.
- W2510230578 isParatext "false" @default.
- W2510230578 isRetracted "false" @default.
- W2510230578 magId "2510230578" @default.
- W2510230578 workType "article" @default.